Sir,

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is approved for the management of advanced lung cancer and other malignancies. Skin complications of erlotinib, such as papulopustular rash, xerosis, or paronychias, are well-known; however, the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) is limited.

A 78-year-old Japanese female with advanced pulmonary adenocarcinoma commenced erolotinib monotherapy 150 mg/day. Facial acneiform rash appeared about a week later, followed by plantar rhagades about 3 weeks later, and both were controlled with topical steroids and emollients. Follow-up chest computed tomography showed that the lung malignancy was responding to erlotinib. Approximately, 80 days after erolotinib induction, multiple palpable purpuric lesions appeared bilaterally on the lower legs, and they gradually increased in number and became more distributed \[[Figure 1a](#F1){ref-type="fig"}\]. The patient denied having a fever, abdominal pain, or arthralgia. Laboratory studies revealed normal platelet counts and coagulability. Renal function was unimpaired, and the results of urinalysis were insignificant. Antineutrophil cytoplasmic antibody titers were not elevated. Skin biopsy demonstrated perivascular infiltration of neutrophils and lymphocytes in the upper dermis, resulting in vascular fibrinoid necrosis with nuclear debris and erythrocytes extravasation \[[Figure 1b](#F1){ref-type="fig"}\]. Direct immunofluorescence revealed C3 complement and fibrinogen deposits around the vessels; however, deposition of immunoglobulin A, M, and G in the vessel wall was not demonstrated. CLCV was diagnosed. Erlotinib was considered to be a possible cause and thus was suspended. Fourteen days after erlotinib was withdrawn, the purpuric lesions disappeared, and the medication was readministered at a reduced dose of 100 mg/day. Purpura has not been observed since.

![(a) Multiple purpuric lesions distributed bilaterally in the lower legs. (b) H and E stained section of a skin biopsy showing perivascular infiltration of inflammatory cells, resulting in fibrinoid necrosis (×100)](IJD-61-238b-g001){#F1}

There have been only five publications regarding CLCV associated with erlotinib,\[[@ref1][@ref2][@ref3][@ref4][@ref5]\] and the purpuric lesions were reported to have appeared 2 weeks to 3 months after erlotinib initiation. In all cases, systemic complications, such as renal failure, abdominal discomfort, and arthralgia, were not mentioned. Boeck was the first to report two cases of CLCV; in both, erlotinib was discontinued, and skin lesions improved with oral steroid therapy, but it was not clarified whether erlotinib was restarted.\[[@ref1]\] Yuba reported successful management of CLCV, not by suspending, but by reducing the erlotinib dosage from 150 mg/day to 100 mg/day;\[[@ref2]\] however, Takahashi reported that skin manifestations were not ameliorated just by reducing the erlotinib dosage, and they eventually improved after erotinib discontinuation.\[[@ref3]\] Su and Brandi successfully managed CLCV, first by suspending, and then by rechallenging with erlotinib at a reduced dose, without recurrence.\[[@ref4][@ref5]\]

When we encounter CLCV, it seems safer to suspend erlotinib, as we cannot be sure that serious systemic vasculitis will not ensue. It was reported to take 2-7 weeks for the skin lesions to heal after erlotinib discontinuation, and systemic steroid administration was not essential. Some consider that CLCV might reflect better anticancer efficacy,\[[@ref5]\] and patients should benefit when we dermatologists know that management of CLCV does not necessarily involve permanent erlotinib cessation. The mechanism of erlotinib-induced CLCV remains not well understood, and it might be a dose-dependent phenomenon, as reduced-dose erlotinib readministration did not reproduce CLCV.
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